title: Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.
abstract: Weight loss and hypolipidemic drugs can improve lipid and adipokine levels. We assessed the effects of rimonabant, alone and in combination with fenofibrate or ezetimibe, on adipokine levels in obese/overweight patients with dyslipidemia. Overweight/obese patients (n = 60, body mass index = 27-40 kg/m(2)) with mixed dyslipidemia were recruited. Patients received a hypocaloric diet and were randomized to rimonabant 20 mg/d (group R, n = 20), rimonabant 20 mg/d plus fenofibrate 200 mg/d (group RF, n = 20), or rimonabant 20 mg/d plus ezetimibe 10 mg/d (group RE, n = 20). After 3 months, leptin concentration was significantly reduced in all groups (-38%, P < .005; -40%, P < .005; and -44%, P < .001 in the R, RF, and RE groups, respectively). Total adiponectin remained unaltered. Visfatin concentration decreased significantly only in the RE and RF groups (-18% and -38%, respectively; P < .047). Treatment with rimonabant may improve adipokine levels in overweight/obese patients with dyslipidemia. The addition of fenofibrate or ezetimibe may reinforce this effect.
authors.affiliation: Department of Internal Medicine, Medical School, University of Ioannina, Ioannina, Greece.
authors.forename: Matilda
authors.initials: M
authors.lastname: Florentin
authors.forename: Evangelos N
authors.initials: EN
authors.lastname: Liberopoulos
authors.forename: Costas C
authors.initials: CC
authors.lastname: Tellis
authors.forename: Christos S
authors.initials: CS
authors.lastname: Derdemezis
authors.forename: Moses
authors.initials: M
authors.lastname: Elisaf
authors.forename: Alexandros
authors.initials: A
authors.lastname: Tselepis
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D000368:Aged; D001384:Azetidines / Q000008:administration & dosage*; D015992:Body Mass Index; D004038:Diet, Reducing; D004359:Drug Therapy, Combination; D050171:Dyslipidemias / Q000097:blood / Q000150:complications / Q000628:therapy; D000069438:Ezetimibe; D005260:Female; D011345:Fenofibrate / Q000008:administration & dosage*; D006801:Humans; D000960:Hypolipidemic Agents / Q000008:administration & dosage*; D008297:Male; D008875:Middle Aged; D009765:Obesity / Q000097:blood / Q000150:complications / Q000628:therapy*; D010880:Piperidines / Q000008:administration & dosage*; D011720:Pyrazoles / Q000008:administration & dosage*; D000077285:Rimonabant; D015431:Weight Loss
chemical_list: D054392:Adipokines; D001384:Azetidines; D000960:Hypolipidemic Agents; D010880:Piperidines; D011720:Pyrazoles; D000069438:Ezetimibe; D000077285:Rimonabant; D011345:Fenofibrate